Lutetium-177 DOTATATE
A somatostatin-analogue peptide that carries radioactive lutetium-177 to neuroendocrine tumours
Lutetium-177 dotatate joins octreotate, a somatostatin analogue, to the chelator DOTA holding lutetium-177. The peptide binds somatostatin receptors and is taken inside the cells that carry them, along with its radiation. The US approved it as Lutathera in 2018 for receptor-positive gastroenteropancreatic neuroendocrine tumours; it slows disease, and its survival benefit is unproven.
What is it?
Many neuroendocrine tumours carry somatostatin receptors, the target of octreotide and lanreotide. Lutathera uses that target as an address: a course is four infusions of 7.4 GBq eight weeks apart, given with long-acting octreotide and an amino acid infusion that, in the label's data, cut the kidneys' median radiation dose by 47%.
The molecule has three parts. Octreotate, an eight-amino-acid somatostatin analogue close to octreotide, binds somatostatin receptor type 2 and is drawn inside the cell. The chelator DOTA holds the lutetium-177 so that it travels with the peptide rather than circulating free. Lutetium-177 emits beta particles that reach about 2 mm into tissue, enough to damage the tumour cell's DNA and neighbouring cells, and it decays with a half-life of 6.647 days.
Its evidence is strongest for slowing disease. In NETTER-1, 229 patients with progressing midgut tumours were randomised to lutetium-177 dotatate or high-dose octreotide: at 20 months 65.2% were alive without progression against 10.8%, and 18% responded against 3%. Quality of life held up longer too; global health status took a median 28.8 months to worsen against 6.1 on octreotide.
Survival is the gap. NETTER-1's final analysis, after a median 76 months, found median overall survival of 48.0 against 36.3 months, a difference that did not reach significance, partly because many control patients later received radioligand therapy.
NETTER-2 moved it earlier. As the first treatment for 226 patients with higher-grade (grade 2 or 3) gastroenteropancreatic tumours, it gave a median progression-free survival of 22.8 months against 8.5 on high-dose octreotide, and the benefit held across grades and in both pancreatic and gastrointestinal tumours. The label now covers children 12 and older; the NETTER-P study in eleven adolescents found no new safety signal at the adult dose.
The kidneys and bone marrow take the radiation that misses the tumour. The label warns of myelosuppression and of secondary myelodysplastic syndrome and leukaemia, with median onsets of 29 and 55 months. FDA's adverse-event reports add carcinoid syndrome and crisis as the strongest post-marketing signals.
It is used beyond its label in other receptor-positive tumours. A 14-patient phase II study in progressive meningioma kept half free of progression at six months, with stable disease rather than shrinkage. These uses rest on small studies; the approval covers gastroenteropancreatic neuroendocrine tumours only.
Mechanism of Action
Lutetium-177 dotatate is a radioligand: a peptide that finds the tumour and a radioactive atom that damages it.
Receptor targeting
Octreotate binds somatostatin receptor type 2 with high affinity and is internalised by the cell (dataset mechanism).
Beta radiation
Lutetium-177 emits beta particles with about a 2 mm range, damaging DNA in the tumour cell and its neighbours; isotope half-life 6.647 days (label 11.1).
Kidney protection
An amino acid infusion before each dose cut the kidneys' median radiation dose by 47% in the label's data.
Published Research
The trials behind lutetium-177 dotatate, read from their PubMed abstracts: NETTER-1 with its quality-of-life and final survival analyses, NETTER-2 and its subgroups, the adolescent study, and FDA's adverse-event reports. Dosing from the Lutathera label read September 30, 2026.
NETTER-1
In 229 patients with progressing midgut tumours, 65.2% on lutetium-177 dotatate were alive without progression at 20 months against 10.8% on high-dose octreotide, and 18% responded against 3%. Severe neutropenia, thrombocytopenia and lymphopenia occurred in 1%, 2% and 9%.
NETTER-1: quality of life
Time until quality of life worsened by 10 points or more was significantly longer on lutetium-177 dotatate (117 patients) than on high-dose octreotide (114): 28.8 against 6.1 months for global health status and 25.2 against 11.5 months for physical functioning; diarrhoea, disease-related worry and body image also held up longer.
NETTER-1: final survival
After a median 76 months, the overall-survival endpoint was not met: median 48.0 months against 36.3 (hazard ratio 0.84, not significant). Two of 111 treated patients developed myelodysplastic syndrome.
NETTER-2: first-line
As first treatment for 226 patients with grade 2 or 3 gastroenteropancreatic tumours, median progression-free survival was 22.8 months against 8.5 on high-dose octreotide (hazard ratio 0.28).
NETTER-2: by grade and origin
Across the 226 randomised patients, lutetium-177 dotatate cut the risk of progression or death against high-dose octreotide in every subgroup tested: grade 2 (hazard ratio 0.31), grade 3 (0.27), pancreatic (0.34) and gastrointestinal (0.23) tumours; median progression-free survival was 29.0 months in grade 2 and 22.2 months in grade 3.
NETTER-P: adolescents
Eleven patients aged 13 to 17 received the adult schedule (7.4 GBq every 8 weeks); low lymphocyte counts were the commonest effect (grade 3 or worse in 5 of 11), no treatment-related kidney toxicity was seen, and projected kidney and marrow doses (21 Gy and 0.76 Gy) were within safety limits. Long-term follow-up continues.
What reports to FDA show
Among 4,284 FDA adverse-event reports from 2019 to 2024, the strongest signals were carcinoid syndrome and carcinoid crisis; some reported events, such as intestinal ischaemia, are not in the label.
Meningioma: an unapproved use
In a 14-patient phase II study in progressive meningioma, half were free of progression at six months, all with stable disease rather than shrinkage, and treatment was well tolerated.
Dosing Data
Given only by teams licensed for radiopharmaceuticals, with antiemetics and an amino acid infusion started 30 minutes before each dose.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
From the Lutathera label (version 12).
Contraindications & Cautions
From the label.
Legal Status
Approved in the US for adults and children 12 and older.
Frequently Asked Questions
?Is it a peptide?
Its targeting part is: octreotate, an eight-amino-acid somatostatin analogue close to octreotide, joined to the chelator DOTA that holds the lutetium-177.
?How long does the radioactivity last?
Lutetium-177 halves every 6.647 days, and the label estimates that over 99% of the given radioactivity leaves the body within 14 days.
?Does it extend life?
It extended progression-free survival in NETTER-1 and NETTER-2, but NETTER-1's final analysis showed no significant overall-survival gain (48.0 against 36.3 months).
?Who can receive it?
Adults and children 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, confirmed by a receptor scan, under the US label.
?Why is octreotide given alongside it?
The label gives long-acting octreotide after each infusion and every four weeks afterwards, for up to 18 months, as in the trials; short-acting forms are stopped beforehand so they do not block the receptors.
?What is the biggest long-term risk?
Marrow damage. The label warns of myelodysplastic syndrome and leukaemia with median onsets of 29 and 55 months; two of 111 treated patients in NETTER-1's final analysis developed myelodysplastic syndrome.
?Has it been tested in children?
In eleven adolescents aged 13 to 17 (NETTER-P), the adult dose gave kidney and marrow radiation within safety limits and no new safety signal; long-term follow-up continues.
?Does it improve quality of life?
In NETTER-1, global health status took a median 28.8 months to worsen on lutetium-177 dotatate against 6.1 months on high-dose octreotide.
References
- [fda-pi] Lutathera (lutetium Lu 177 dotatate) injection US prescribing information (DailyMed version 12, effective January 15, 2026); read September 30, 2026.
- [clinical-trial] Strosberg J, et al. "Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors." N Engl J Med, 2017;376(2):125-135. PMID: 28076709.
- [clinical-trial] Strosberg JR, et al. "(177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial." Lancet Oncol, 2021;22(12):1752-1763. PMID: 34793718.
- [clinical-trial] Singh S, et al. "[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study." Lancet, 2024;403(10446):2807-2817. PMID: 38851203.
- [pubmed] Chen H, et al. "Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System." Clin Nucl Med, 2025;50(8):714-720. PMID: 40310018.
- [clinical-trial] Kurz SC, et al. "Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma." Clin Cancer Res, 2024;30(4):680-686. PMID: 38048045.
- [clinical-trial] Ferone D, et al. "[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial." EClinicalMedicine, 2026;98:104109. PMID: 42604001.
- [clinical-trial] Strosberg J, et al. "Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial." J Clin Oncol, 2018;36(25):2578-2584. PMID: 29878866.
- [clinical-trial] Gaze MN, et al. "Safety and dosimetry of [(177)Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study." Eur J Nucl Med Mol Imaging, 2025;52(11):4001-4015. PMID: 40198358.
Sources & Citations
Dosing, warnings and pharmacokinetics from the Lutathera label (DailyMed version 12, effective January 15, 2026, read September 30, 2026); approval from Drugs@FDA; studies from PubMed abstracts.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.